Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

CHMP positive for treatment of plaque psoriasis with Cosentyx in children and adolescents aged 6 to <18 years.- Novartis

Written by | 27 Jun 2020

Novartis, announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Cosentyx (secukinumab) for the treatment… read more.

CHMP positive for treatment of plaque psoriasis with Cosentyx in children and adolescents aged 6 to <18 years.- Novartis

Written by | 27 Jun 2020

Novartis, announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Cosentyx (secukinumab) for the treatment… read more.

CHMP positive for treatment of plaque psoriasis with Cosentyx in children and adolescents aged 6 to <18 years.- Novartis

Written by | 27 Jun 2020

Novartis, announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Cosentyx (secukinumab) for the treatment… read more.

Results from interim analysis of RESOLVE-IT phase III trial of elafibranor in adults with NASH and fibrosis. Genfit

Written by | 12 May 2020

Genfit announced results from an interim analysis of the RESOLVE-IT Phase III trial evaluating once-daily, 120mg of elafibranor in adults with non-alcoholic steatohepatitis (NASH). The trial did not… read more.

CHMP recommends Cosentyx for the treatment of adult patients with active non-radiographic axial spondyloarthritis. -Novartis

Written by | 29 Mar 2020

Novartis, announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Cosentyx (secukinumab) for the treatment… read more.

World Health Matters: Germany: Concern over hepatitis B among refugees

Written by | 5 Sep 2016

by Gary Finnegan: People seeking refuge and asylum in Germany are at higher risks of liver problems due to hepatitis B, according to experts.

ILTS 2016: Professors John Lake (University of Minnesota, MN, USA) and John O’Grady (Kings College Hospital, London) discuss what’s novel in immuno-suppression. Also associated article included on Immunosuppression.

Written by | 13 Jun 2016

Biomarkers emerging as guide on immunosuppression by Thomas R. Collins Using the right amount of immunosuppression treatment, but no more than necessary, is a challenge facing clinicians handling… read more.

ILTS 2016: Professors John Lake (University of Minnesota, MN, USA) and John O’Grady (Kings College Hospital, London) discuss what's novel in immuno-suppression. Also associated article included on Immunosuppression.

Written by | 13 Jun 2016

Biomarkers emerging as guide on immunosuppression by Thomas R. Collins Using the right amount of immunosuppression treatment, but no more than necessary, is a challenge facing clinicians handling… read more.

ILTS 2014: Liver-directed cellular therapy – hope or hype?

Written by | 7 Aug 2014

Feature Symposium.  Stephen Strom, Karolinska Institutet, Stockholm, Sweden.   Luc van der Laan, Erasmus Medical Center, Rotterdam, the Netherlands.  Alberto Sanchez-Fueyo, King’s College Hospital, London, UK.  David Hay, University… read more.

ITLS 2014: Liver transplantation – aspiring to excellence: Current challenges and cutting edge developments

Written by | 6 Aug 2014

Report from the Joint International Congress of ILTS, ELITA and LICAGE 2014.   Recurrence of hepatitis C virus (HCV) infection after transplantation is a major challenge for centres all… read more.

ILTS 2014: State of the art lecture: Transplantation or medical care for acute liver failure

Written by | 6 Aug 2014

Report from the Joint International Congress of ILTS, ELITA and LICAGE 2014.  Roger Williams, Institute of Hepatology/Foundation for Liver Research, London, UK.   Medical care after acute liver failure… read more.

ESOT 2013 Report – Retransplantation of abdominal organs

Written by | 23 Oct 2013

Re-transplantation is the only option available for salvaging a failed abdominal graft. As the outcomes after primary transplantations continue to improve, even with the increasing use of extended-criteria… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.